164 related articles for article (PubMed ID: 7684798)
1. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia.
Coustan-Smith E; Behm FG; Hurwitz CA; Rivera GK; Campana D
Leukemia; 1993 Jun; 7(6):853-8. PubMed ID: 7684798
[TBL] [Abstract][Full Text] [Related]
2. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
3. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
4. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
5. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.
Venditti A; Del Poeta G; Stasi R; De Fabriitis P; Coppetelli U; Bruno A; Simone MD; Papa G
Haematologica; 1993; 78(6):359-63. PubMed ID: 7513673
[TBL] [Abstract][Full Text] [Related]
6. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
9. Intracellular markers in acute myeloid leukemia diagnosis.
Koníková E; Glasová M; Kusenda J; Babusíková O
Neoplasma; 1998; 45(5):282-91. PubMed ID: 9921916
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
11. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
12. [Distribution of antigenic aberration in the bone marrow of acute leukemia in complete remission].
Shin S; Kahng J; Kim M; Lim J; Kim Y; Han K
Korean J Lab Med; 2008 Feb; 28(1):1-7. PubMed ID: 18309249
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.
Macedo A; Orfao A; Ciudad J; Gonzalez M; Vidriales B; Lopez-Berges MC; Martínez A; Landolfi C; Cañizo C; San Miguel JF
Leukemia; 1995 Nov; 9(11):1896-901. PubMed ID: 7475281
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
16. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
17. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
18. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in acute myeloid leukemia.
Gerhartz HH; Schmetzer H
Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Terstappen LW; Safford M; Könemann S; Loken MR; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Leukemia; 1992 Jan; 6(1):70-80. PubMed ID: 1540262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
